Evotec SE
As of Oct 22, 2026, Evotec is in Stage 4, the downtrend phase, now in week 16 (since Jul 6, 2026). It closed at $1.54, 62.9% below its 52-week high and below its 200-day average, which is falling.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is EVO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
EVO among Drug Manufacturers - Specialty & Generic62nd of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …62 | EVO | Stage 4 · wk 16 | 18 | 0.0% |
Evotec: quick answers
What stage is Evotec in?
As of Oct 22, 2026, Evotec (EVO) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 6, 2026 and is in week 16. What the four stages mean
Is Evotec in an uptrend?
No. Evotec is in a Stage 4 downtrend. It trades 40.4% below its 200-day average, which is falling.
How far is Evotec from its 52-week high?
Evotec closed at $1.54 on Oct 22, 2026, 62.9% below its 52-week high of $4.15. Its 52-week low is $1.35.
How has Evotec performed over the past year?
As of Oct 22, 2026, Evotec is down 61.6% over the past year and down 51.6% so far in 2026.
Which sector and industry is Evotec in?
Evotec is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.